A review of the latest executive moves in the pharma industry over the past several months.
Posts
A Phase II trial studying PTC Therapeutics’ PTC518 in Huntington’s disease (HD) has been paused in the United States following a request from the FDA for additional data, the company announced Tuesday afternoon.
